Tickers

1. Composite Trajectory Verdict

For a commercial-stage biopharmaceutical company with a marketed product and recent second-product launch, the income statement and cash flow statement carry the most weight because they reflect the sustainability of commercial operations and the ability to fund ongoing R&D without external financing; the balance sheet is secondary but relevant for liquidity runway.

Composite Trajectory: Mixed

Revenue is growing annually (13% in 2025) and quarterly (32% in Q2 2026 YoY), driven by volume gains and the April 2026 launch of Lifyorli. However, profitability has deteriorated sharply on an annual basis: 2025 operating income fell 67% to $44.8M despite higher revenue, and net income declined 29% to $99.7M, as SG&A surged 60% to $448.7M. Quarterly trends are volatile: Q2 2026 operating income rose 54% YoY to $41.3M, but YTD 2026 shows an $8.3M operating loss versus a $30.1M gain in YTD 2025 due to a Q1 2026 operating loss of $49.6M. Operating cash flow declined 28% annually (2025 vs 2024) and 66% YTD (June 2026 vs June 2025). The balance sheet shows growing equity ($705.8M at June 2026 vs $647.8M at December 2025) and stable liquidity ($544.6M cash+marketable securities at June 2026 vs $532.4M at December 2025), but the annual cash decline and rising accrued rebates bear monitoring.

2. Red Flags

• SG&A growing far faster than revenue: Annual SG&A jumped 60% to $448.7M in 2025 while revenue grew 13%; Q2 2026 SG&A rose 51% YoY to $156.9M on 32% revenue growth; Q1 2026 SG&A rose 60% YoY to $145.4M on 5% revenue growth (10-K 2025-12-31, MD&A Results of Operations; 10-Q 2026-06-30, MD&A Results of Operations; 10-Q 2026-03-31, MD&A Results of Operations).
• Operating income collapse despite revenue growth: 2025 operating income fell 67% to $44.8M from $137.0M in 2024 (10-K 2025-12-31, Consolidated Statements of Operations). YTD 2026 operating loss of $8.3M vs $30.1M gain in YTD 2025 (10-Q 2026-06-30, Consolidated Statements of Operations).
• Operating cash flow declining: Annual operating cash flow dropped 28% to $142.0M in 2025 from $198.3M in 2024 (10-K 2025-12-31, MD&A Liquidity and Capital Resources). YTD June 2026 operating cash flow fell 66% to $16.8M from $49.1M in YTD June 2025 (10-Q 2026-06-30, MD&A Liquidity and Capital Resources).
• Large share repurchases while operating cash flow falls: $172.9M spent on stock repurchase program in 2025 (10-K 2025-12-31, MD&A Liquidity and Capital Resources) versus declining operating cash flow; no repurchases in YTD 2026 (10-Q 2026-06-30, Consolidated Statements of Cash Flows).
• Specialty pharmacy transition constrained 2025 revenue: Management stated 2025 net product revenue "would have been materially higher had our primary specialty pharmacy vendor been able to fully meet demand" (10-K 2025-12-31, MD&A Results of Operations).
• Regulatory setback for relacorilant in hypercortisolism: FDA issued CRL December 30, 2025; NDA resubmitted June 17, 2026 with PDUFA date December 17, 2026 (10-Q 2026-06-30, MD&A Overview).
• IRA expected to materially reduce profits from 2026 onward: Company anticipates Inflation Reduction Act provisions "will limit the revenue we receive from Medicare patients and may materially reduce our profits in 2026 and beyond" (10-K 2025-12-31, MD&A Inflation Reduction Act; 10-Q 2026-06-30, MD&A Inflation Reduction Act).
• Accrued government rebates rising sharply: Short-term accrued rebates increased to $45.9M at June 2026 from $35.7M at December 2025; long-term accrued rebates rose to $6.1M from $2.6M (10-Q 2026-06-30, Notes to Financial Statements, Note 2).
• Accounts payable dropped 63% sequentially: Fell to $14.9M at June 2026 from $40.4M at December 2025 (10-Q 2026-06-30, Consolidated Balance Sheets), a large working capital shift not explicitly explained.

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual revenue grew consistently: $482.4M (2023) → $675.0M (2024, +40%) → $761.4M (2025, +13%) (10-K 2025-12-31, Consolidated Statements of Operations). However, operating income peaked at $137.0M in 2024 then fell 67% to $44.8M in 2025 as SG&A exploded from $280.3M to $448.7M (+60%) and R&D rose 3% to $254.9M (10-K 2025-12-31, Consolidated Statements of Operations). Net income followed: $106.1M (2023) → $141.2M (2024) → $99.7M (2025). Quarterly trends diverge: Q2 2026 revenue $256.1M (+32% YoY) with operating income $41.3M (+54% YoY) (10-Q 2026-06-30, Consolidated Statements of Operations), but Q1 2026 revenue $164.9M (+5% YoY) produced a $49.6M operating loss vs $3.4M gain in Q1 2025 (10-Q 2026-03-31, Consolidated Statements of Operations). YTD 2026 shows an $8.3M operating loss versus $30.1M gain in YTD 2025. Lifyorli contributed $47.6M in Q2 2026 (launched April 2026) (10-Q 2026-06-30, Consolidated Statements of Operations). Hypercortisolism Products revenue growth slowed to 7% YoY in Q2 2026 and 6% YTD (10-Q 2026-06-30, MD&A Results of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Annual operating cash flow declined 28% to $142.0M in 2025 from $198.3M in 2024, after rising 56% in 2024 (10-K 2025-12-31, MD&A Liquidity and Capital Resources). The decrease was attributed to "lower net income resulting from higher operating expenses to support increased sales and marketing activities" (ibid). YTD June 2026 operating cash flow plummeted 66% to $16.8M from $49.1M in YTD June 2025 (10-Q 2026-06-30, MD&A Liquidity and Capital Resources). Q1 2026 alone used $16.8M in operations versus $4.8M provided in Q1 2025 (10-Q 2026-03-31, MD&A Liquidity and Capital Resources). Investing cash flow swung to a $24.7M outflow in YTD 2026 from a $67.0M inflow in YTD 2025, driven by higher marketable securities purchases (10-Q 2026-06-30, Consolidated Statements of Cash Flows). Financing outflows dropped dramatically to $1.3M in YTD 2026 from $142.7M in YTD 2025, primarily because the stock repurchase program was inactive in 2026 versus $130.5M in YTD 2025 (10-Q 2026-06-30, Consolidated Statements of Cash Flows). Total cash and marketable securities fell 12% annually to $532.4M at December 2025 from $603.2M at December 2024 (10-K 2025-12-31, MD&A Liquidity and Capital Resources), but edged up 2% to $544.6M at June 2026 (10-Q 2026-06-30, MD&A Liquidity and Capital Resources).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Stable

Stockholders' equity increased to $705.8M at June 2026 from $647.8M at December 2025, driven by retained earnings growth to $654.6M from $643.4M and additional paid-in capital rising to $1,048.6M from $968.6M (10-Q 2026-06-30, Consolidated Balance Sheets). Total assets grew to $888.7M from $836.7M over the same period. Cash and marketable securities stood at $544.6M at June 2026 versus $532.4M at December 2025 (10-Q 2026-06-30, MD&A Liquidity and Capital Resources). Current assets declined to $439.7M from $485.5M, mainly due to lower short-term marketable securities ($197.2M vs $251.7M) and trade receivables ($76.9M vs $59.8M higher, but cash lower). Current liabilities fell to $153.8M from $166.1M, led by accounts payable dropping to $14.9M from $40.4M and accrued R&D falling to $21.6M from $34.0M, partially offset by accrued and other liabilities rising to $115.3M from $90.6M (10-Q 2026-06-30, Consolidated Balance Sheets). Long-term accrued government rebates increased to $6.1M from $2.6M. No debt is reported; lease liabilities total $9.4M present value (10-Q 2026-06-30, Note 5). The equity base is solid and liquidity adequate, but the annual decline in cash+marketable securities (from $603.2M at Dec 2024 to $532.4M at Dec 2025) and rising rebate accruals warrant attention.

6. Data Gaps

• Full-year 2026 results (only six months available).
• Quarterly data for Q3 2025 and Q4 2025 (only annual aggregates in 10-K).
• Detailed SG&A breakdown (e.g., sales vs marketing vs G&A) beyond aggregate figures.
• Revenue split between Korlym and authorized generic for full year 2025 (only described qualitatively).
• Cash flow statement for standalone Q2 2026 (only YTD provided in 10-Q).
• Debt maturity schedule beyond operating lease commitments.
• Impact of IRA provisions quantified (only qualitative warning given).
• 2023 balance sheet details (only 2024 and 2025 in 10-K XBRL).